Anti-Infective Drugs

2023

 
TDM Education India Webinar – June 7, 2023

• Saliva point of care TDM – Prof. Jan Willem Alffenaar
• Overview of TDM in Seth GSMC and KEM Hospital Mumbai – Dr. Mahesh Belhekar
• TDM in patients on hemodialysis – Dr. Bhaskar Krishnamurthy

 
TDM Education India Webinar – April 5, 2023

• Use of simple ordinary differential equations based pharmacokinetic models for personalized dose recommendation – Dr. Anand Srinivasan
• Principles and Practice of TDM – Dr. Sumith Mathew

 
TDM Education India Webinar – February 1, 2023

• Role of TDM of colistin in critically Ill patients – Dr. Surya S
• Therapeutic drug monitoring of antimicrobial agents: essential, optional or a waste of time? The anecdotal experiences of an Infectious Diseases physician – Dr. Debbie Marriott

2022

 
TDM Education India Webinar – December 7, 2022

• Drug-Drug Interactions and TDM – Dr. Florian Lemaitre
• Population Pharmacokinetics of Colistin – a path towards dose optimization – Dr. Manjunath Nookala Krishnamurthy

 
Fast and Furious: Pithy Practice Points from the Anti-Infectives Committee Members Webinar – October 12, 2022

• Stephanie Reuter Lange, Australia
• Paul Chin, New Zealand
• Jana Stojanova, Australia
• Carsten Müller, Germany
• Sumith Mathew, India
• Dario Cattaneo, Italy
• Danijela Kocic, Australia
• Gauri Rao, USA
• Michael Neely, USA

 
Validation of Bioanalytical Methods Webinar – September 7, 2022

• Validation parameters for Bioanalytical method – Dr. Nanda Gamad
• Walking through an example of method validation – Dr. Ritika Kondel
• External Proficiency Testing in TDM Laboratory – Dr. Soumya Vij and Dr. Naveen Murali

 
TDM Education India Webinar – August 3, 2022

• Principles of HPLC – Dr. Vishnu Eriyat
• Relevance of TPMT Phenotyping in the Indian Population – Prof Ratna Prabha

 
JSTDM-IATDMCT Joint Symposium for TDM in Asia-Pacific Region – May 21, 2022

• Mycophenolate TDM in Indian Population: Opportunities and Challenges – Dr. Smita Pattanaik
• Implementation of model informed precision dosing into routine clinical practice – Dr. Sophie Stocker
• Gentamicin Population Pharmacokinetics in Malaysian Neonates treated in NICU – Dr. Suzana Mustafa
• Pharmacokinetic study of anti-viral drugs for patients with COVID-19 – Dr. Kei Irie

 
IATDMCT Latin American Regional Meeting – March 18, 2022

• Day 1
  • Logistics of running a TDM laboratory – Dr. Danijela Kocic, Australia
  • Selecting the right bioanalytical approach – A/Prof Dario Cattaneo, Italy
  • Capillary microsampling strategies in bioanalysis for TDM and toxicology – Prof Rafael Linden, Brazil
  • TDM of anti-tuberculous drugs – Prof Jan-Willem Alffenaar, Australia
  • Implementation of a TDM service – Dr. Sophie Stocker, Australia
  • Barriers to clinical implementation of TDM – Dr. Jane Carland, Australia
  • Precision dosing in a tertiary care paediatric hospital in Argentina. Outcomes and challenges – Dr. Paula Schiaquevich, Argentina
  • Round table discussion – Chair, Prof. Debbie Marriott
• Day 2
  • Use of free tissue concentrations at the infection site to establish antimicrobial’s treatment – Prof Teresa Dalla Costa, Brazil
  • Building pharmacometrics capabilities in Latin America: Opportunities in the clinical setting – A/Prof Manuel Ibarra, Uruguay
  • Artificial intelligence/machine learning: a real opportunity for non-parametric approaches – Prof Andres Zuluaga, Colombia
  • Better patient care with precision dosing – Prof Michael Neely, USA
  • Clinical utility of TDM – Prof Debbie Marriott, Australia
  • Clinical pharmacokinetics, a Chilean perspective – Dr. Leslie Escobar, Chile
  • Evaluation of TSM services – Dr. Jana Stojanova, Australia/Chile
  • TDM in intensive care – Prof Jason Roberts
  • TDM in Latin America – the next phase: Round table discussion – Chair, A/Prof. Dario Cattaneo

2021

 
Regional Anti-Infectives TDM meeting – Singapore, November 2021 (to replace the event scheduled for November 4, 2020 and then cancelled for the Covid-19 pandemic)
 
TDM workshop IATDMCT Asia-Pacific Regional Meeting – 29, 30 October, 2021

• Day 1
  • TDM in Asia – Associate Professor Miao Yan
  • Logistics of running a TDM laboratory – Dr. Danijela Kocic, Australia
  • Selecting the right bioanalytical approach – Associate Professor Dario Cattaneo
  • TDM services in a Malaysian hospital: starting from scratch with baby steps – Dr. Lee Lee Low
  • TDM services in a tertiary hospital laboratory – Dr. Jayme Wong Sau Yeng
  • TDM in intensive care – Professor Jason Roberts
• Day 2
  • Clinical utility of TDM – Professor Debbie Marriott
  • Evaluation of TDM services – Dr. Jana Stojanova
  • Barriers to clinical implementation of TDM – Dr. Jane Carland
  • Implementation of a TDM service – Dr. Sophie Stocker
  • TDM of anti-tuberculous drugs – Professor Jan-Willem Alffenaar
  • TDM in anti-microbial resistance – Dr. Tze-Peng Lim

 
Asia-Pacific Conference on Clinical Microbiology and Infections, a well-respected conference attracting over 1000 delegates. It is anticipated that approximately 80 participants will attend. The ability to use speakers already invited to the APCCMI (Debbie Marriott, Jason Roberts) will reduce costs to IATDMCT. The Singapore Infectious Diseases Society has generously offered to provide their conference organizing facilities for our regional meeting.

Scientific Contributions

2022

 
Reuter SE, Stocker SL, Alffenaar JC, Baldelli S, Cattaneo D, Jones G, Koch BCP, Kocic D, Mathew SK, Molinaro M, Neely M, Sandaradura I, Marriott DJE. Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement From the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2022 Feb 1;44(1):121-132. doi: 10.1097/FTD.0000000000000944. PMID: 34882107.
 
Kim HY, Baldelli S, Märtson AG, Stocker S, Alffenaar JW, Cattaneo D, Marriott DJE. Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2022 Feb 1;44(1):198-214. doi: 10.1097/FTD.0000000000000931. PMID: 34654030.
 

2021

 
Roberts JA, Joynt GM, Lee A, Choi G, Bellomo R, Kanji S, Mudaliar MY, Peake SL, Stephens D, Taccone FS, Ulldemolins M, Valkonen MM, Agbeve J, Baptista JP, Bekos V, Boidin C, Brinkmann A, Buizen L, Castro P, Cole CL, Creteur J, De Waele JJ, Deans R, Eastwood GM, Escobar L, Gomersall C, Gresham R, Jamal JA, Kluge S, König C, Koulouras VP, Lassig-Smith M, Laterre PF, Lei K, Leung P, Lefrant JY, Llauradó-Serra M, Martin-Loeches I, Mat Nor MB, Ostermann M, Parker SL, Rello J, Roberts DM, Roberts MS, Richards B, Rodríguez A, Roehr AC, Roger C, Seoane L, Sinnollareddy M, Sousa E, Soy D, Spring A, Starr T, Thomas J, Turnidge J, Wallis SC, Williams T, Wittebole X, Zikou XT, Paul SK, Lipman J; SMARRT Study Collaborators and the ANZICS Clinical Trials Group. The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study. Clin Infect Dis. 2021 Apr 26;72(8):1369-1378. doi: 10.1093/cid/ciaa224. PMID: 32150603.
 

2020

 
Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, Neely MN, Paiva JA, Pea F, Sjovall F, Timsit JF, Udy AA, Wicha SG, Zeitlinger M, De Waele JJ, Roberts JA. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#. Intensive Care Med 46, 1127–1153 (2020). https://doi.org/10.1007/s00134-020-06050-1
Infection Section of European Society of Intensive Care Medicine (ESICM)
Pharmacokinetic/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC)
 
Märtson AG, Sturkenboom MGG, Stojanova J, Cattaneo D, Hope W, Marriott D, Patanwala AE, Peloquin CA, Wicha SG, van der Werf TS, Tängdén T, Roberts JA, Neely MN, Alffenaar JC. How to design a study to evaluate therapeutic drug monitoring in infectious diseases? Clin Microbiol Infect. 2020 Aug;26(8):1008-1016. doi: 10.1016/j.cmi.2020.03.008. Epub 2020 Mar 21. PMID: 32205294.
 
Cattaneo D, Corona A, De Rosa FG, Gervasoni C, Kocic D, Marriott DJ. The management of anti-infective agents in intensive care units: the potential role of a ‘fast’ pharmacology. Expert Rev Clin Pharmacol. 2020 Apr;13(4):355-366. doi: 10.1080/17512433.2020.1759413. Epub 2020 May 4. PMID: 32320302.
 
Rao GG, Konicki R, Cattaneo D, Alffenaar JW, Marriott DJE, Neely M; IATDMCT Antimicrobial Scientific Committee. Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics. Ther Drug Monit. 2020 Feb;42(1):83-92. doi: 10.1097/FTD.0000000000000710. PMID: 31652190.
 
Cattaneo D, Baldelli S, Cozzi V, Clementi E, Marriott DJE, Gervasoni C; IATDMCT Anti-Infective Committee. Impact of Therapeutic Drug Monitoring of Antiretroviral Drugs in Routine Clinical Management of People Living With HIV: A Narrative Review. Ther Drug Monit. 2020 Feb;42(1):64-74. doi: 10.1097/FTD.0000000000000684. PMID: 31393332.
 
Kim HY, Märtson AG, Dreesen E, Spriet I, Wicha SG, McLachlan AJ, Alffenaar JW. Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. Front Pharmacol. 2020 Jun 12;11:894. doi: 10.3389/fphar.2020.00894. PMID: 32595511; PMCID: PMC7304296.
 
 

Compass Contributions

2023

Who, What, When, Where, How, Why of TDM of linezolid
Cindy Lau, Deborah Marriott, Jonathan Penm, Jan-Willem Alffenaar
 

2022

TDM PRACTICES IN VIETNAM
Anh Xuong Ha, Anh Thi Nguyen
 

2021

Therapeutic drug monitoring of echinocandins. Has the time come?
Deborah Marriott
 
Potential risks of complementary alternative medicines in people living with HIV: the experience at the GAP Clinic
Dario Cattaneo
 
 

IATDMCT Conference Symposium Contributions

2024

 
22nd Congress, September 15-18, Banff

• The mysteries of target site concentrations of antibiotics in hard to reach infections: an evolving application of TDM?
  • TDM of long-acting antibiotics for long-term use – Milo Gatti, Italy
  • Stability issues and potential role of TDM for outpatient parenteral antibiotic therapies – Birgit Koch, Netherlands
  • Deciphering and quantifying the penetration of antibiotics in the tissues – Iris K. Minichmayr, Austria
  • Using saliva as an alternative matrix to conduct TDM of antibiotics – Thi Nguyen, Australia

• Dish of the Day
  • Fluconazole – the last azole to optimize? – Isabel Spriet, Belgium
  • Navigating the beta-lactam therapeutic window – Rekha Pai Mangalore, Australia
  • Catching the Culprit: Benzylpenicillin Neurotoxicity Confirmed by TDM in a Critically Ill Patient With CVVH – Maaike Sikma, Netherlands
  • Vancomycin dosage optimization for pediatric patients with special disease conditions – Yuko Shimamoto, Japan
  • Non-renal augmented clearance of linezolid – Jana Stojanova, Australia

• Children are not small adults: paving the road to PK/PD dose optimization of anti-infectives in children
  • Precision dosing of anti-infectives in children – big solution for small people? – Pieter De Cock, Belgium
  • Use of physiologically-based pharmacokinetic modelling for dose optimization of antibiotics in children – Samuel Dubinsky, Canada
  • Implementing model-informed precision dosing of antibiotics at Cincinnati Children’s Hospital Medical Center – Sonya Tang Girdwood, USA
  • Hybrid use of machine learning and population PK/PD to optimize anti-infectives dosing in children – Wei Zhao, China

• Breakfast Roundtable
  • Use of the hollow fiber infection model to generate PK-PD targets in humans (Joint with PMx Committee) – Michael Neely, USA

2023

 
21st Congress, September 24-27, Oslo

• Anti-infectives TDM studies and endpoints
  • Lessons Learned, most promising drugs to study – Birgit Koch
  • Biomarkers – Indy Sandaradura
  • Which endpoint to choose – Michael Neely
  • TDM in countries with other resources, focus on costs – Joao Paulo Marochi Telles

2022

 
20th Congress, September 18-21, Prague

• TDM in the management of infections of implantable devices
  • Infections of implanted cardiac devices – Deborah Marriott
  • Infections of orthopedic protheses – Philip Drennan
  • Relevance of plasma concentrations to biofilm exposure – Indy Sandaradura
• Antibiotics
  • Expression of circulating microRNAs in septic patients treated with nephrotoxic antibiotic agents – Nadezda Petejova
  • Paediatric cystic fibrosis patients as a special population benefiting from therapeutic drug monitoring guided medicine dosing: recent advances including new therapeutic options, life quality and expectancy – Hundie Tesfaye
  • Nephrotoxicity of vancomycine after implementation of higher therapeutic range – Blanka Koristkova

2021

 
19th Congress, September 19-22, Rome

• Infection site measurement of anti-microbial agents: unnecessary, a luxury or essential?
  • Bone and joint infections – Birgit Koch
  • Lungs and pleural space – Federico Pea
  • The role of microdialysis – Markus Zeitlinger